Teva Pharmaceutical Industries (NYSE:TEVA) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA - Free Report) from a hold rating to a buy rating in a research note published on Friday.

Several other research analysts have also commented on TEVA. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research report on Friday, January 17th. Barclays decreased their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Bank of America dropped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Finally, UBS Group decreased their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Down 2.9 %

Shares of NYSE:TEVA traded down $0.41 during midday trading on Friday, reaching $13.54. The company had a trading volume of 12,351,322 shares, compared to its average volume of 9,797,887. The stock has a market capitalization of $15.35 billion, a P/E ratio of -9.33, a PEG ratio of 1.44 and a beta of 0.72. The stock's fifty day moving average price is $16.10 and its 200-day moving average price is $17.93. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries has a one year low of $12.51 and a one year high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Institutional Trading of Teva Pharmaceutical Industries

A number of large investors have recently modified their holdings of TEVA. FMR LLC grew its position in Teva Pharmaceutical Industries by 30.7% in the 4th quarter. FMR LLC now owns 81,983,231 shares of the company's stock worth $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Duquesne Family Office LLC boosted its position in shares of Teva Pharmaceutical Industries by 530.1% during the fourth quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after buying an additional 7,569,450 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its holdings in Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after buying an additional 4,418,961 shares in the last quarter. Todd Asset Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter valued at approximately $58,243,000. Finally, Marshall Wace LLP raised its stake in Teva Pharmaceutical Industries by 87.8% during the 4th quarter. Marshall Wace LLP now owns 5,155,402 shares of the company's stock valued at $113,625,000 after acquiring an additional 2,410,420 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.